Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback